stockrow
Saturday 7 November 2026
Export PTIX’s income statement to Excel — free account
Atrinsic Inc.
PTIX Healthcare Biotechnology
- EPS
- +61.3%
- Free cash flow
- +46.1%
Quarter to June 2026, against a year earlier
0.54
0.09
−14.29%
Follow PTIX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 33 | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (2) | (3) | (2) | (3) | (5) | (4) | (5) | (6) | (4) | 1 | 5 | n/m | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (2) | (3) | (2) | (3) | (5) | (4) | (5) | (6) | (4) | 1 | 5 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (12.34) | (13.96) | (9.56) | (13.81) | (17.19) | (11.53) | (16.12) | (15.79) | (0.67) | 0.59 | 2.23 | n/m | ||||||
| Cash flow | (7.53) | (5.85) | (2.66) | (7.31) | (10.64) | (6.47) | (11.94) | (12.05) | (0.33) | (1.21) | (1.10) | (18.4%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.48) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (7.53) | (5.85) | (2.66) | (7.31) | (10.64) | (6.47) | (12.42) | (12.05) | (0.33) | (1.21) | (1.10) | (18.4%) | ||||||
| Book value | 6.66 | (1.15) | (3.46) | (6.23) | 37.79 | 22.44 | 11.83 | 2.90 | (0.92) | 1.12 | 0.95 | (17.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 2 | +32.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | 0 | (1) | (3) | (2) | (4) | (4) | (2) | (3) | (2) | +8.2% | |||||
| Capex | — | — | — | — | — | 0 | 0 | — | — | 0 | 0 | +16.4% | ||||||
| Free cash flow | (1) | (1) | 0 | (1) | (3) | (2) | (4) | (4) | (2) | (3) | (2) | +8.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | 0 | 0 | 0 | 10 | 7 | 4 | 1 | (5) | 1 | 0 | (9.2%) | |||||
| Net debt | (2) | (1) | (1) | 1 | (10) | (8) | (4) | (2) | 0 | (2) | (1) | (1.2%) | ||||||
| Shareholders’ equity | 1 | 0 | (1) | (1) | 10 | 7 | 4 | 1 | (5) | 3 | 2 | +8.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (91.43) | (206.42) | (227.51) | (296.10) | (75.77) | (37.24) | (80.91) | (175.98) | (351.29) | 73.16 | 378.63 | +164.6 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (253.66) | (229.86) | (253.7) pt | ||||||
| ROE | (122.26) | (507.24) | 414.27 | 285.71 | (102.88) | (42.18) | (94.48) | (236.06) | 182.34 | (117.22) | (338.24) | +5.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | — | 2 | — | (4.4%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Jun 2013 · latest quarter Sep 2011 · fundamentals updated 26 Oct 2026
Atrinsic Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABPO Abpro Holdings Inc. | $1.4M | 0.5× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $1.4M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| ELAB PMGC Holdings Inc. | $1.3M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | |
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $1.3M | — | — | −5.93% | — | −16.91% | 14.76% | 0.00% |
Pay and ownership Proxy statement filed 5 December 2025
Ownership
Directors and executive officers, together
8.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement